PMGC Holdings Inc
ELAB
View Detailed Chart
5.820USD
-0.280-4.59%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
8.60MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-4.59%
5 Days
+21.76%
1 Month
+193.94%
6 Months
+3.19%
Year to Date
-63.69%
1 Year
-98.64%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. The Company’s portfolio consists of three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC. Northstrive Biosciences Inc. is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Its lead asset, EL-22, is leveraging a first-in-class engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. PMGC Research Inc. is a research and development subsidiary of the Company, which is focused on advancing the frontiers of scientific discovery. PMGC Capital LLC is a multi-strategy investment vehicle engaging in investing, lending, and seeking diversified investment opportunities across various markets.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 246.93.
Overvalued
The company’s latest PE is 0.03, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 45.85K shares, decreasing 43.06% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.78K shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. The Company’s portfolio consists of three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC. Northstrive Biosciences Inc. is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Its lead asset, EL-22, is leveraging a first-in-class engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. PMGC Research Inc. is a research and development subsidiary of the Company, which is focused on advancing the frontiers of scientific discovery. PMGC Capital LLC is a multi-strategy investment vehicle engaging in investing, lending, and seeking diversified investment opportunities across various markets.
Ticker SymbolELAB
CompanyPMGC Holdings Inc
CEOMr. Graydon Bensler
Websitehttps://pmgcholdings.com/
Related Instruments
+0.31%
+0.67%
+0.69%
+0.04%
+0.15%
-0.08%
+2.88%
-1.01%
+0.28%
-0.05%
-1.66%
-0.63%
-1.31%
-0.18%
+0.22%
-0.35%
-2.13%
-4.24%
-0.85%
0.00%
